Browse by Person

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | No Grouping
Jump to: Article
Number of items: 4.

Article

Twelves, C, Awada, A, Cortes, J et al. (6 more authors) (2016) Subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer. Breast Cancer: Basic and Clinical Research, 10. pp. 77-84.

Cortes, J, Hudgens, S, Twelves, C et al. (7 more authors) (2015) Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial. Breast cancer research and treatment, 154 (3). 509 - 520. ISSN 0167-6806

Kaufman, PA, Awada, A, Twelves, C et al. (7 more authors) (2015) Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane. Journal of Clinical Oncology, 33 (6). pp. 594-601. ISSN 0732-183X

Kaufmann, PA, Cortes, J, Awada, A et al. (8 more authors) (2013) A Phase Ill, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: Subgroup analyses. Onkologie: international journal for cancer research and treatment, 36 (Suppl 7). p. 97. ISSN 0378-584X

This list was generated on Sun Aug 18 23:33:11 2019 BST.